Abstract
Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Current Pharmaceutical Design
Title: Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Volume: 17 Issue: 18
Author(s): Sylvia S. Singh and Peter M. Kang
Affiliation:
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Abstract: Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Export Options
About this article
Cite this article as:
S. Singh Sylvia and M. Kang Peter, Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796390994
DOI https://dx.doi.org/10.2174/138161211796390994 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention
Current Vascular Pharmacology Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?
Current Vascular Pharmacology Potentiating the Naturally Occurring Process for Repair of Damaged Heart
Current Pharmaceutical Design Urine IL-18 is a Biomarker of Early Acute Kidney Injury (AKI)
Recent Patents on Biomarkers Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research
Current Alzheimer Research The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Turner Syndrome : How Is It Made Up?
Current Genomics Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Insight γ-Secretase: Structure, Function, and Role in Alzheimer’s Disease
Current Drug Targets